Table 1 Study characteristics

From: Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: Cochrane review

Study

Participants

Interventions

Outcomes

Allocation concealment

EORTC 10851 (UK) n=164 (Fentiman et al, 2003)

Women (aged 70+) with operable breast cancer

Surgery (mastectomy; full axillary clearance) vs tamoxifen (20 mg day−1)

Survival - overall; PFS; local disease control; distant metastasis free survival

A

Nottingham 1 (UK) n=131 (Kenny et al, 1998)

Women (aged 70+) with operable breast cancer

Surgery (wedge mastectomy; limited axillary surgery) vs tamoxifen (40 mg day−1)

Survival - overall; PFS; local disease control; distant metastasis free survival

B

St Georges (UK) n=200 (Gazet et al, 1994)

Women (aged 70+) with operable breast cancer

Surgery (mastectomy or wide local excision without radiotherapy; axillary surgery not specified) vs tamoxifen (20 mg day−1)

Survival - overall; PFS; local disease control; distant metastasis free survival

B

CRC (UK) n=455 (Fennessey et al, 2004)

Women (aged 70+) with operable breast cancer

Surgery (mastectomy or wide local excision without radiotherapy; axillary surgery not specified) plus tamoxifen (40 mg day−1) vs tamoxifen alone

Survival - overall; PFS; local disease control; distant metastasis free survival; psychiatric and social morbidity

A

GRETA (Italy) n=274 (Mustacchi et al, 2003)

Women (aged 70+) with operable breast cancer

Surgery (mastectomy or wide local excision with radiotherapy; axillary clearance) plus tamoxifen (20 mg day−1) vs tamoxifen alone

Survival - overall; PFS; local disease control; distant metastasis free survival

A

Naples (Italy) n=75 (Capasso et al, 2000)

Women (aged 70+) with operable breast cancer

Surgery (mastectomy or wide local excision with radiotherapy;±axillary clearance) plus tamoxifen (20 mg day−1) vs tamoxifen alone

Survival - overall; PFS

B

Nottingham 2 (UK) n=147 (Willsher et al, 1997)

Women (aged 70+) with operable breast cancer

Surgery (wedge mastectomy; limited axillary surgery) plus tamoxifen vs tamoxifen (20 mg day−1)

Survival - overall; PFS

B

  1. PFS=progression-free survival.
  2. Surgery vs primary endocrine therapy.
Back to article page